In a blog post at the Maternal Health Task Force, Ann Blanc, Vice President of Social and Behavioral Science Research at the Population Council, makes a powerful case for why investing in high-quality research matters, now more than ever.
In a blog post for FHI 360’s Contraceptive Technology Innovation Exchange, Julia Bunting, President of the Population Council, and Laneta Dorflinger, Distinguished Scientist and Director for Contraceptive Technology, outline what needs to be done to increase access to the broadest choice of quality, affordable, and acceptable contraceptives.
This summer, the Population Council's Nestorone®/Testosterone transdermal gel, a new topical gel that blocks sperm production, will begin a Phase IIb clinical trial. The trial will start in the U.S. before being expanded to Britain, Italy, Sweden, Chile, and Kenya.
Council researcher Nanlesta Pilgrim writes about the U.S. Food and Drug Administration (FDA)'s recent decision to expand the approval of Truvada as pre-exposure prophylaxis (PrEP) against HIV for use in at-risk adolescents and the continued need to improve services for adolescents, in the U.S. and around the world.
In a blog post for FHI 360’s Contraceptive Technology Innovation Exchange, the Council’s Saumya RamaRao, senior associate, and Loreley Villamide-Herrera, biomedical program manager, highlight the latest advances in the novel drug delivery platform of vaginal rings.
Several promising male contraceptive products are currently making their way through clinical trials, Vox writes, including Nestorone®/Testosterone transdermal gel, a new topical gel that blocks sperm production.
During the UN Commission on the Status of Women (CSW), new Population Council insights about the power of research to understand, measure, and encourage abandonment of female genital mutilation/cutting (FGM/C) were highlighted through high-level events and press coverage.